#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myotonic dystrophy Extra-osseous Ewing's sarcoma recurrent Fibrosarcoma metastatic Palmar-plantar erythrodysaesthesia syndrome Paroxysmal nocturnal haemoglobinuria Niemann-Pick disease Fallopian tube cancer NTRK gene fusion overexpression Hepatic cirrhosis Hypergammaglobulinaemia benign monoclonal Malignant fibrous histiocytoma Immune thrombocytopenia Anti-HLA antibody test positive Isodicentric chromosome 15 syndrome Chronic lymphocytic leukaemia refractory More trials…

    Learn about Rare Diseases

    MELAS syndrome – Trials in Disease Splenic marginal zone lymphoma – Trials in Disease Uterine leiomyosarcoma – Diagnostics Rhabdomyosarcoma – Treatment Methylmalonic acidaemia – Basic Information Pituitary-dependent Cushing’s syndrome – Diagnostics Nephrotic syndrome – Trials in Disease Gaucher’s disease type I – Treatment Ornithine transcarbamoylase deficiency – Trials in Disease KBG syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    A52 Palopegteriparatide Emrusolmin Nvdx3 Lucerastat Larotrectinib Sulfate Bemcentinib Ceftolozane Teprotumumab Carfilzomib Migalastat IMMUNOSTEM Calcium Polystyrene Sulfonate Itepekimab RP2 Cefaclor ARGININE GLUTAMATE Sodium Nitrite Atropine Sulfate Colecalciferol More therapies…

    Learn about Your Condition

    Mucopolysaccharidosis Lichenoid keratosis Asthmatic crisis Immunodeficiency Hepatic cirrhosis Septic shock Plasma cell leukaemia Urticaria chronic Cerebral haemorrhage Postprandial hypoglycaemia Fallopian tube cancer stage IV Wiskott-Aldrich syndrome Chronic hepatic failure Anxiety Ovarian cancer metastatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Istituto Oncologico Veneto

Istituto Oncologico Veneto

Via Gattamelata 64, Padua, 35128, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Pembrolizumab with Chemotherapy for Patients with Gastric or Gastroesophageal Junction Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Adenocarcinoma gastric
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Capecitabine
    • Cisplatin
    Belgium Estonia France Germany Italy Latvia +2

  • Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Datopotamab Deruxtecan
    Austria Bulgaria France Germany Greece Hungary +4

  • Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine Hydrochloride
    • Nivolumab
    Austria Belgium Finland France Germany Greece +5

  • Study of Durvalumab, Tremelimumab, and Bevacizumab for Patients with Non-Resectable Liver Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Durvalumab
    • Tremelimumab
    Germany Italy

  • Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Durvalumab
    • Glucose
    • Infliximab
    Belgium France Germany Greece Italy The Netherlands +2

  • Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Paclitaxel
    • Ramucirumab
    • Trastuzumab Deruxtecan
    Belgium France Germany Hungary Ireland Italy +4

  • Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cetrelimab
    • Cisplatin
    • Gemcitabine
    Austria Belgium Czechia France Germany Greece +4

  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Central nervous system melanoma
    • Gastrointestinal melanoma
    • Malignant melanoma
    Investigated Drugs:
    • Binimetinib
    • Encorafenib
    • Ipilimumab
    Germany Italy Poland Slovakia Spain

  • Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    • Infliximab
    • Mycophenolate Mofetil
    Czechia France Germany Italy The Netherlands Poland +2

  • Study Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Datopotamab Deruxtecan
    • Eribulin Mesylate
    Belgium France Germany Hungary Italy Poland +1
Previous Page
1 … 33 34 35 36 37 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!